<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04718402</url>
  </required_header>
  <id_info>
    <org_study_id>HE071-CSP-014</org_study_id>
    <nct_id>NCT04718402</nct_id>
  </id_info>
  <brief_title>A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma</brief_title>
  <official_title>A Multicenter, Open-label, Single-arm, Phase Ib Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Gastric Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and&#xD;
      efficacy of Mitoxantrone Hydrochloride Liposome in subjects with advanced gastric carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and&#xD;
      efficacy of Mitoxantrone Hydrochloride Liposome in subjects with advanced gastric carcinoma.&#xD;
      At least 30 subjects will be recruited in this study. The subjects will receive Mitoxantrone&#xD;
      Hydrochloride Liposome 20 mg/m2 by an intravenous infusion (IV), every 21 days (q3w, 1&#xD;
      cycle). All patients will receive the treatment until disease progression, intolerable toxic&#xD;
      reaction, death, or withdrawal by investigator or patient decision (a maximum of 8 cycles).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">January 19, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 19, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse events (AEs)</measure>
    <time_frame>From the initiation of the first dose to 28 days after the last dose, assessed up to 36 months</time_frame>
    <description>The incidence and severity of AEs, abnormalities in physical exams, vital sign assessments, clinical laboratory assessments, ultrasonic cardiograms (UCGs) and electrocardiographs (ECGs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate (ORR)</measure>
    <time_frame>From the enrollment to the final documentation of response of the last subject (assessed up to 36 months)</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response (DoR)</measure>
    <time_frame>From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of complete response (DCR)</measure>
    <time_frame>From the enrollment to the final documentation of response of the last subject (assessed up to 36 months)</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Gastric Carcinoma</condition>
  <arm_group>
    <arm_group_label>Mitoxantrone Hydrochloride Liposome Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with advanced gastric carcinoma will receive 20mg/m2Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone Hydrochloride Liposome, intravenous injection</intervention_name>
    <description>All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).</description>
    <arm_group_label>Mitoxantrone Hydrochloride Liposome Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects fully understand and voluntarily participate in this study and sign informed&#xD;
             consent;&#xD;
&#xD;
          2. Age ≥18, without gender limitation;&#xD;
&#xD;
          3. Histologically confirmed diagnosis of unresectable locally advanced or metastatic&#xD;
             gastric carcinoma, including gastroesophageal junction carcinoma;&#xD;
&#xD;
          4. Suitable to receive the study drug as decided by the investigator;&#xD;
&#xD;
          5. At least one measurable lesion according to RECIST v1.1;&#xD;
&#xD;
          6. ECOG performance status of 0 to 2;&#xD;
&#xD;
          7. Life expectancy ≥ 12 weeks;&#xD;
&#xD;
          8. AEs from the previous treatment have resolved to ≤ Grade 1 based on CTCAE (except for&#xD;
             the toxicity without safety risk judged by the investigator, such as hair loss,&#xD;
             hyperpigmentation);&#xD;
&#xD;
          9. Adequate organ function;&#xD;
&#xD;
         10. Subjects of childbearing potential must agree to use effective contraceptive measures.&#xD;
             Female subjects must have a negative pregnancy test before enrolment;&#xD;
&#xD;
         11. Fully comply with the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergy to mitoxantrone hydrochloride or any excipients of the study drug;&#xD;
&#xD;
          2. Untreated or symptomatic central nervous system (CNS) metastases;&#xD;
&#xD;
          3. Amenable to curative surgery ( radical excision);&#xD;
&#xD;
          4. Pleural effusion, pericardial effusion or peritoneal effusion with overt clinical&#xD;
             symptoms (except for those have a drainage within 1 month before screening,&#xD;
             asymptomatic and the effusion only detectable by imageological examination);&#xD;
&#xD;
          5. Intestinal obstruction with overt clinical symptom and requiring treatment;&#xD;
&#xD;
          6. CTCAE Grade 3 or Grade 4 gastrointestinal hemorrhage within 12 weeks prior to the&#xD;
             first dose administration;&#xD;
&#xD;
          7. History of allotransplantation;&#xD;
&#xD;
          8. Known hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus&#xD;
             (HIV) or other active viral infection;&#xD;
&#xD;
          9. Serious infection or interstitial pneumonia within 1 week prior to the first dose&#xD;
             administration;&#xD;
&#xD;
         10. Use of other anticancer treatment within 4 weeks prior to the first dose&#xD;
             administration;&#xD;
&#xD;
         11. Enrolled in any other clinical trails and had recieved treatment within 4 weeks prior&#xD;
             to the first dose administration;&#xD;
&#xD;
         12. Major surgery within 3 months prior to the first dose administration, or have a&#xD;
             surgical schedule during the study period;&#xD;
&#xD;
         13. Thrombosis or thromboembolism within 6 months prior to screening;&#xD;
&#xD;
         14. History of, or known additional malignant tumor within 3 years, except for tumors have&#xD;
             been cured and have not recurred, and carcinoma in situ;&#xD;
&#xD;
         15. Impaired cardiac function or serious cardiac disease;&#xD;
&#xD;
         16. Previous treatment with adriamycin or other anthracyclines, and the total cumulative&#xD;
             dose of prior adriamycin or equivalent is &gt;350 mg/m2.&#xD;
&#xD;
         17. Pregnant or lactating female;&#xD;
&#xD;
         18. Serious and/or uncontrolled systemic diseases;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jieer Ying, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital of The University of Chinese Academy of Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuefang Xia</last_name>
    <phone>010-63932012</phone>
    <email>xiaxuefang@mail.ecspc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Luhe Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101149</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Yan, Doctor</last_name>
      <phone>13621308215</phone>
      <email>yd15yt88@163.com</email>
    </contact>
    <investigator>
      <last_name>Dong Yan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rongbo Lin, Bachelor</last_name>
      <phone>13705919382</phone>
      <email>rongbo_lin@163.com</email>
    </contact>
    <investigator>
      <last_name>Rongbo Lin, Bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lanzhou University Second Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hao Chen, MD</last_name>
      <phone>15009467790</phone>
      <email>chenhaodrs@163.com</email>
    </contact>
    <investigator>
      <last_name>Hao Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hebei General Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qingxia Li, MD</last_name>
      <phone>13613110158</phone>
      <email>lqx73@163.com</email>
    </contact>
    <investigator>
      <last_name>Qingxia Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei Medical University and Hebei Cancer Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050019</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruixing Zhang, MD</last_name>
      <phone>13831120299</phone>
      <email>zrx@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Ruixing Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qun Zhao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jufeng Wang, Master</last_name>
      <phone>13783583966</phone>
      <email>13783583966@163.com</email>
    </contact>
    <investigator>
      <last_name>Jufeng Wang, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liu Yang, MD</last_name>
      <phone>13666601475</phone>
      <email>yangliuqq2003@163.com</email>
    </contact>
    <investigator>
      <last_name>Liu Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of The University of Chinese Academy of Science</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jieer Ying, MD</last_name>
      <phone>13858195803</phone>
      <email>jieerying@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Jieer Ying, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taizhou Hospital of Zhejiang Province</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <zip>317000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianying Jin, Master</last_name>
      <phone>13867656027</phone>
      <email>302861459@qq.com</email>
    </contact>
    <investigator>
      <last_name>Jianying Jin, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

